It has already been approved for the treatment of HER2-positive breast cancer, gastric cancers, non-small-cell lung cancer with an HER2 mutation, as well as being observedly beneficial in OC treatment [15,16]. The gene discussed is ERBB2; the disease is gastric cancer.